Under Armour, Inc. (UAA): Burden Shifts to UAA to Reinforce its Revenue Algo

Under Armour, Inc. (UAA): Burden Shifts to UAA to Reinforce its Revenue Algo

UBS thinks the category remains much more promotional than UAA anticipated

Consumer Discretionary

Under Armour, Inc. (UAA): Burden Shifts to UAA to Reinforce its Revenue Algo

UBS thinks the category remains much more promotional than UAA anticipated

Netflix, Inc. (NFLX): We Think That $30 of EPS Over Time is Possible

MKM Partners continues to believe the global opportunity for Netflix is very large and still open

Shopify Inc. (NYSE:SHOP): Beatable Numbers, But Tougher Risk-Reward

RBC Capital Markets thinks 2Q17 estimates are beatable, but RBC does not like the risk-reward

Amazon.com, Inc. (AMZN): Expecting Solid 2Q17 Results

Cantor Fitzgerald expects another solid quarter, with 22.5% Y/Y revenue growth

Technology

Facebook (FB) Positive Post in a Continuing Multi-Year Story

UBS sees Facebook continuing to surprise on balancing engagement & monetization

Facebook Inc (FB) Continues to Hit on All Cylinders

Wedbush is maintaining OUTPERFORM rating and raising 12-month price target to $225 from $185.

Advanced Micro Devices, Inc. (AMD): Execution Continues but Shares Continue to Appear Appropriately Valued

MKM Partners still sees shares as full valued at current levels given medium-term sales and earnings growth prospects

Apple Inc (AAPL): Supply chain tight, maintain Outperform

Credit Suisse reiterates Outperform rating and PT of $170

Advanced Micro Devices (AMD): Upside Seems Priced In

Morgan Stanley does not see earnings growing into the stock price, and Morgan Stanley maintains a cautious view

Micron Technology Inc. (MU): Continue to see a positive trade in Micron Stock

Morgan Stanley continues to see Micron climbing a wall of cynicism and worry as memory is likely to remain robust near term

Energy

First Solar Inc. (FSLR): Will the Near Term Momentum will Continue?

Deutsche Bank gives Reasons Why Near term Momentum Could Continue

Apache Corporation (APA) Exiting Canada At Modest Price

In June, APA also agreed to sell its Provost assets in Alberta to an undisclosed private company

ONEOK, Inc. (OKE) Aggressive Dividend Growth Targets With An Opaque Opportunity Set

When contemplating the future, however, Morgan Stanley is concerned about Bakken exposure in a lower oil price environment well as limits to NGL uplift potential should Permian production continue to grow rapidly

Exxon Mobil Corporation (XOM) Generates The Highest Downstream Returns

Exxon has a sustained track record and corporate reputation for quality of assets, reliability of performance and a tenacious focus on seeking competitive advantage and superior returns

Healthcare

Vertex Pharmaceuticals Inc (VRTX): Orkambi Beats Estimates; Focus Is On Triple Combinations Now

Maxim Group states that Vertex is poised to unlock up to 90% of the CF (cystic fibrosis) market, which reflects a larger heterozygote market and the best case

Sarepta Therapeutics Inc. (SRPT): 4Q Dystrophin Data A Key Catalyst

Morgan Stanley sees Clean beat with no red flags; expect SRPT up 5-10%

Incyte Corporation (INCY) Competitor MYSTIC IO/IO PFS Expected Imminently

PFS results are anticipated mid-2017 and final OS data in 2018. Notably, several interim analyses for OS are included in trial protocol, and it is unclear what information will be provided to the public

Celgene Corporation (CELG): Ozanimod Worth $19/sh, Range Is $12-25 on RRMS & IBD Results

Today Leerink is publishing its second of two notes on Celgene Corporation’s (NASDAQ:CELG) ozanimod that focuses on the product’s value; in its current forecast the firm estimates that ozanimod is worth $19/ share (13% of its PT) in the base case scenario in its model